Hughes, Brett G.M.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., et al. (2012) · Clinical Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 415

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Fong, L., Hotson, A., Powderly, J. D., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G. M., Hellmann, M. D., Shepard, D. R., et al. (2020) · Cancer Discovery

Adenosine and Purinergic SignalingCancer Immunotherapy and Biomarkers

Cited by 352

Phase IB Trial of the Anti‐Cancer Stem Cell DLL4‐Binding Agent Demcizumab with Pemetrexed and Carboplatin as First‐Line Treatment of Metastatic Non‐Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L., et al. (2018) · Targeted Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 74